Time to evolve trial design after everolimus failure

Josep M. Llovet

doi:10.1038/nrclinonc.2014.136

Related publications

Preprint2024

Soil multifunctionality co-evolve with food web coupling after glacier retreat

Yanbao Lei, Jie Shen, Weitao Li, Kunkun Fan, Teng Yang, Ya‐Huang Luo, Yakov Kuzyakov, Manuel Delgado‐Baquerizo, Yu Shi, Geng Sun

Authorea (Authorea)

Article2018

TCT-1 Optimal Duration of Dual Antiplatelet Therapy After Left Main Coronary Stenting With Everolimus-Eluting Stents: Analysis From the EXCEL Trial

Sorin J. Brener, Patrick W. Serruys, Martin B. Leon, Marie‐Claude Morice, David E. Kandzari, Roxana Mehran, A. Pieter Kappetein, Joseph F. Sabik, Yangbo Liu, Ovidiu Dressler, Ori Ben‐Yehuda, Gregg W. Stone

Journal of the American College of Cardiology

Article2010

Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial

Yosinobu Onuma, Patrick W. Serruys, John A. Ormiston, Evelyn Regar, Mark Webster, Leif Thuesen, Dariusz Dudek, Susan Veldhof, Richard Rapoza

EuroIntervention

Article2010

Abstract 17174: Predictors of Stent Thrombosis after Everolimus-Eluting and Paclitaxel-Eluting Stents: The Pooled SPIRIT Randomized Trial Experience at Two Years of Follow-Up

Ajay J. Kirtane, Poornima Sood, Robert J. Applegate, Manejeh Yaqub, Yoshinobu Onuma, John C. Wang, Xiaolu Su, Karine Miquel‐Hébert, Alexandra J. Lansky, Dean J. Kereiakes, Charles A. Simonton, Krishnankutty Sudhir, Patrick W. Serruys, Gregg W. Stone

Circulation

Article2013

TCT-429 Short- and intermediate- term clinical outcomes after implantation of everolimus-eluting bioresorbable scaffold in complex lesions : a prospective single-arm study - ABSORB Expand trial

Robert J. Van Geuns, Peter de Jaegere, Roberto Diletti, Αντώνιος Καρανάσος, Takashi Muramatsu, Sjoerd T. Nauta, Yoshinobu Onuma, Evelyn Regar, Carl Schultz, Patrick W. Serruys, Nicolas M. Van Mieghem, Felix Zijlstra